Cargando…
Mortality in SARS-CoV-2 Hospitalized Patients Treated with Remdesivir: A Nationwide, Registry-Based Study in Italy
Remdesivir is the first drug approved for treatment of COVID-19 but current evidence for recommending its use for the treatment of moderate-to-severe disease is still controversial among clinical guidelines. We performed a nationwide, registry-based study including all Italian hospitalized patients...
Autores principales: | Russo, Pierluigi, Tacconelli, Evelina, Olimpieri, Pier Paolo, Celant, Simone, Colatrella, Antonietta, Tomassini, Luca, Palù, Giorgio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9228114/ https://www.ncbi.nlm.nih.gov/pubmed/35746668 http://dx.doi.org/10.3390/v14061197 |
Ejemplares similares
-
Real-life comparison of mortality in patients with SARS-CoV-2 infection at risk for clinical progression treated with molnupiravir or nirmatrelvir plus ritonavir during the Omicron era in Italy: a nationwide, cohort study
por: Torti, Carlo, et al.
Publicado: (2023) -
How many chronic myeloid leukemia patients who started a frontline second‐generation tyrosine kinase inhibitor have to switch to a second‐line treatment? A retrospective analysis from the monitoring registries of the italian medicines agency (AIFA)
por: Breccia, Massimo, et al.
Publicado: (2020) -
Trabectedin use in soft‐tissue sarcoma patients in a real‐world setting: Data from an Italian national drug‐access registry
por: Vincenzi, Bruno, et al.
Publicado: (2022) -
Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency
por: Rigolin, Gian Matteo, et al.
Publicado: (2023) -
COVID-19 and School Activities in Italy
por: Sebastiani, Giovanni, et al.
Publicado: (2020)